R-Equol-plus-Equol-DataSheet-生命科學(xué)試劑-MedChemExpress_第1頁
R-Equol-plus-Equol-DataSheet-生命科學(xué)試劑-MedChemExpress_第2頁
R-Equol-plus-Equol-DataSheet-生命科學(xué)試劑-MedChemExpress_第3頁
R-Equol-plus-Equol-DataSheet-生命科學(xué)試劑-MedChemExpress_第4頁
全文預(yù)覽已結(jié)束

下載本文檔

版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進行舉報或認(rèn)領(lǐng)

文檔簡介

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemE(R)-EquolCat. No.: HY-108414CAS No.: 221054-79-1Synonyms: (+)-Equol分式: CHO分量: 242.27作靶點: Estrogen Receptor/ERR作通路: Others儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實驗 DMSO : 100 mg/mL (412.76 mM

2、; Need ultrasonic and warming)Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 4.1276 mL 20.6381 mL 41.2763 mL5 mM 0.8255 mL 4.1276 mL 8.2553 mL10 mM 0.4128 mL 2.0638 mL 4.1276 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度,選擇合適的溶劑配制儲備液,并請注意儲備液的保存式和期限。體內(nèi)實驗請根據(jù)您的實驗動物和給藥式選擇適當(dāng)?shù)娜芙獍?,配制前請先配制澄的儲備液,再依次添加助溶?為保證實驗結(jié)果的可靠性,體內(nèi)實驗的作液,建議您現(xiàn)現(xiàn)配,

3、當(dāng)天使;澄的儲備液可以根據(jù)儲存條件,適當(dāng)保存;以下溶劑前的百分 指該溶劑在您配制終溶液中的體積占):1. 請依序添加每種溶劑: 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (10.32 mM); Clear solution2. 請依序添加每種溶劑: 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (10.32 mM); Clear solution3. 請依序添加每種溶劑: 10% DMSO 90% corn oil1/3 Master of

4、Small Molecules 您邊的抑制劑師www.MedChemESolubility: 2.5 mg/mL (10.32 mM); Clear solutionBIOLOGICAL ACTIVITY物活性 (R)-EquolER 和 ER 的激動劑,Ki 值分別為 27.4 和 15.4 nM。IC50 & Target Ki: 27.4 nM (ER), 15.4 nM (ER) 1體外研究 (R)-Equol is an agonist of both ER and ER with Kis of 27.4 and 15.4 nM, respectively 1. (R)-Equoli

5、nduces a dose-dependent inhibitory effect on the invasive capacity of MDA-MB-231 cells that is significant atthe highest concentration tested (50 M). Following 48-h exposure to (R)-Equol, invasion is reduced by 62%(p=0.009, versus untreated cells) with 50 M (R)-Equol. Matrix metalloproteinase-2 (MMP

6、-2) expression issignificantly down-regulated following treatment with 50 M (R)-Equol (p=0.035) 2.體內(nèi)研究 Animals fed (R)-Equol have a significantly reduced number of palpable tumors over time when compare withControls (P=0.002). Furthermore, the number of palpable tumors formed per rat in the (R)-Equo

7、l-fed group issignificantly lower than that of rats treated with S-(-)equol (P=0.008). (R)-Equol-fed animals have 43% fewertumors than the control group and this difference is highly statistically significant (P=0.004). The number oftumors/tumor-bearing animal is significantly lower in the animals f

8、ed (R)-Equol compare with Controls(3.30.4 versus 5.50.5, P=0.004). At necropsy, the mean (SEM) tumor weight per animal for (R)-Equol fedrats (5.31.1 mg) is significantly reduced (P=0.04) when compare with Controls (9.91.4 mg). Feeding the(R)-Equol diet results in significantly increased tumor latenc

9、y (P=0.003) 3.PROTOCOLCell Assay 2 Cell viability is determined using the well-established MTT assay. Cells are seeded (1.25105 cells/mL) in96-well plates in experimental medium (100 L/well) and incubated for 48 h at 37C in a 95 % air/5 % CO2humidified atmosphere. Medium is then replaced with fresh

10、medium containing (R)-Equol (R-equol) (2.5, 10or 50 M) or DMSO only as a control. Following 48-h incubation, cell viability is assessed 2.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal To investigate the chemopreventive effects of dietary (R)-Eq

11、uol against chemically induced mammaryAdministration 3 cancer, female Sprague-Dawley rats bred in-house are fed a soy-free AIN-93G diet from birth to 35 days ofage, then separated into different groups. Group 1 (Control group, n=40) continues on this diet, whereas theother group of animals are fed t

12、he AIN-93G diet supplemented with 250 mg/kg of (R)-Equol (Group 3, n=41)beginning on day 35 until killing on day 190 3.MCE has not independently confirmed the accuracy of these methods. They are for reference only.REFERENCES1. Setchell KD, et al. S-equol, a potent ligand for estrogen receptor beta,

13、is the exclusive enantiomeric form of the soy isoflavonemetabolite produced by human intestinal bacterial flora. Am J Clin Nutr. 2005 May;81(5):1072-9.2/3 Master of Small Molecules 您邊的抑制劑師www.MedChemE2. Magee PJ, et al. Daidzein, R-(+)equol and S-(-)equol inhibit the invasion of MDA-MB-231 breast cancer cells potentially via the down-regulation of matrix metalloproteinase-2. Eur J Nutr. 2014 Feb;53(1):345-50.3. Brown NM, et al. The chemopreventive action of equol enantiomers in a chemically induced animal model of breast cancer.Carcinogenesis. 2010 May;31(5):

溫馨提示

  • 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。

評論

0/150

提交評論